Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1A | P54750 | 6/20 | 0.41 |
| ▸ | PDE1B | Q01064 | 6/20 | 0.41 |
| ▸ | PDE1C | Q14123 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.37 |
| ▸ | DHFR | P00374 | 2/20 | 0.35 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4528709 | 0.85 | ADORA2A (0.41) | PDE1APDE1BPDE1CTGFBR1TLR8 | |
| SCHEMBL4533730 | 0.83 | DHFR (0.35) | PDE1APDE1BPDE1CTGFBR1TLR8 | |
| SCHEMBL3759373 | 0.82 | NOS1 (0.40) | PDE1APDE1BPDE1CMAPTALOX5AP | |
| SCHEMBL4512860 | 0.81 | DHFR (0.50) | TLR8DHFRGAAL3MBTL1 | |
| SCHEMBL4534714 | 0.81 | ADORA2A (0.42) | PDE1APDE1BPDE1CTLR8DHFR | |
| SCHEMBL4522776 | 0.81 | L3MBTL1 (0.54) | MAPTTLR8DHFRPDCD1LG2CD274 | |
| SCHEMBL4524229 | 0.80 | PTPN1 (0.48) | PDE1APDE1BPDE1CTLR8TLR7 | |
| SCHEMBL4536401 | 0.80 | HSP90AA1 (0.47) | MAPTTLR8DHFR | |
| SCHEMBL4524970 | 0.80 | TRPV3 (0.35) | PDE1APDE1BPDE1CMAPTTGFBR1 | |
| SCHEMBL4528794 | 0.79 | PTPN1 (0.45) | MAPTPDCD1LG2CD274GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232278-B2 | Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C | GILEAD SCIENCES, INC. (US) | 2012-07-31 | — | — | US | claimed |
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | GILEAD SCIENCES, INC. (US) | 2009-05-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | DPYD, TYMP, PNPO | PDE1A 4589/4885PDE1B 4467/4885PDE1C 4245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.